Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Anna Berkenblit"'
Autor:
Yaping Tu, Eva Hanze, Fengying Zhu, Maxime Lagraauw, Callum Sloss, Michael Method, Brooke Esteves, Eric Westin, Anna Berkenblit
Aims: Mirvetuximab soravtansine is the first-in-class antibody-drug conjugate approved in November 2022 for the treatment of folate receptor-α positive ovarian cancer. The aim of this study was to develop a population pharmacokinetic (PK) model to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb888b928c21bf771759f5cf6fee7a92
https://doi.org/10.22541/au.167533208.87309627/v1
https://doi.org/10.22541/au.167533208.87309627/v1
Autor:
Kathleen N. Moore, Amit M. Oza, Conleth G. Murphy, Nicoletta Colombo, Giovanni Scambia, J. Wang, P.C. Lim, Jason A. Konner, Bradley J. Monk, Anna Berkenblit, Michael J. Birrer, Patricia Pautier, H. Hirte, M. Prasad-Hayes, Ana Oaknin, Ignace Vergote, Susana Banerjee, Domenica Lorusso, Janos L. Tanyi, Gottfried E. Konecny
Publikováno v:
Scientia
Chemotherapy; Mirvetuximab soravtansine; Ovarian cancer Quimioterapia; Mirvetuximab soravtansina; Cáncer de ovarios Quimioteràpia; Mirvetuximab soravtansina; Càncer d'ovaris Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab500045f9eb68bf0669cf8d0f50c90f
https://lirias.kuleuven.be/handle/20.500.12942/692015
https://lirias.kuleuven.be/handle/20.500.12942/692015
Autor:
John M. Lambert, Anna Berkenblit
Publikováno v:
Annual Review of Medicine. 69:191-207
The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to the challenge of increasing the therapeutic index of cell-killing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d499a2605af8c836992798987569bffc
https://doi.org/10.1146/annurev-med-061516-121357
https://doi.org/10.1146/annurev-med-061516-121357
Autor:
Ying Su, Kathleen N. Moore, Lainie P. Martin, Jason A. Konner, Michael J. Birrer, Ursula A. Matulonis, Rodrigo Ruiz-Soto, Shelly Seward, Anna Berkenblit, Raymond P. Perez
Publikováno v:
Gynecologic oncology
Purpose To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients. Methods Patients with ovarian tumors amenable to biopsy were eligible to enroll. Eligibility included a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1da3942cab811b4ee886fa2b73ae3588
https://doi.org/10.1016/j.ygyno.2017.08.015
https://doi.org/10.1016/j.ygyno.2017.08.015
Autor:
Revathi Ananthakrishnan, Birgit Geoerger, Jill S. Clancy, Sheri L. Spunt, Joseph Boni, Mizue Krygowski, Stephan A. Grupp, Anna Berkenblit, Danuta Perek, Mark W. Kieran
Publikováno v:
European Journal of Cancer. 48:253-262
A phase II study of temsirolimus was conducted in children and adolescents with high-grade glioma, neuroblastoma or rhabdomyosarcoma.Temsirolimus 75 mg/m(2) was administered once weekly until disease progression or intolerance. Using the Simon 2-stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756895d4f713b21dfd7addbf758b8f74
https://doi.org/10.1016/j.ejca.2011.09.021
https://doi.org/10.1016/j.ejca.2011.09.021
Autor:
Mizue Krygowski, J. P. Maroto, Charles S. White, Theodore F. Logan, Ignacio Duran, Gary R. Hudes, Mark Shapiro, Anna Berkenblit, Maria Cincotta, Janice P. Dutcher
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose Pneumonitis has occurred in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). In a phase III study of patients with previously untreated, poor-prognosis, advanced renal cell carcinoma (ARCC), the mTOR inhibitor tem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d11aaa554e4b3d318224b527e305239
https://doi.org/10.1200/jco.2010.29.2235
https://doi.org/10.1200/jco.2010.29.2235
Autor:
Anna Berkenblit, Michael J. Birrer, Lainie P. Martin, Ursula A. Matulonis, David M. O'Malley, Kathleen N. Moore, Lucy Gilbert, Ignace Vergote, Cesar M. Castro
Publikováno v:
Gynecologic Oncology. 149:38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5896e03c74fc8f221396fc92696db1f
https://doi.org/10.1016/j.ygyno.2018.04.085
https://doi.org/10.1016/j.ygyno.2018.04.085
Autor:
Andrew Strahs, Robert DeMarinis, Gary R. Hudes, Anna Berkenblit, Donna Levy, Arthur S. Zbrozek, Shreekant Parasuraman
Publikováno v:
PharmacoEconomics. 28(7):577-584
Background and Objective:Background and Objective: For patients with advanced cancers, it is important that treatment improves the quality as well as the quantity of survival. This quality-adjusted time without symptoms of progression or toxicity (Q-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301c2da7eec1c908144b23db41e74b18
http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201028070-00005.pdf
http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201028070-00005.pdf
Autor:
Michael Crump, Andrew Strahs, Orysia Hanushevsky, Raoul Herbrecht, Christian Gisselbrecht, Laurence Moore, Jorge E. Romaguera, Gregor Verhoef, Anna Laurell, Jill S. Clancy, Becker Hewes, Anna Berkenblit, Bertrand Coiffier, Fritz Offner, Georg Hess
Publikováno v:
Journal of Clinical Oncology. 27:3822-3829
Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7234ed4fd49227464dced565648ea934
https://doi.org/10.1200/jco.2008.20.7977
https://doi.org/10.1200/jco.2008.20.7977
Publikováno v:
Annals of Oncology. 19:1387-1392
Background Temsirolimus, a novel inhibitor of mammalian target of rapamycin, has demonstrated prolonged overall survival and progression-free survival compared with interferon alfa (IFN) in patients with advanced renal cell carcinoma (RCC) and poor p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae4ed4955eea0421ef6109dae1730492
https://doi.org/10.1093/annonc/mdn066
https://doi.org/10.1093/annonc/mdn066